NeuroThera said the platform has now completed an end-to-end hybrid quantum-classical workflow in a quantum simulation environment, extending earlier validation toward integrated clinical data analytics.
SciSparc Ltd. said its majority-owned subsidiary NeuroThera Labs Inc. has advanced its quantum sampling platform for clinical trial analytics from internal workflow validation to a complete end-to-end hybrid quantum-classical process in a quantum simulation environment. The company said the platform can ingest and prepare real-world clinical data, apply quantum-enabled analytical processing and generate biologically and clinically interpretable insights within a fully integrated framework. The platform’s proprietary analytical architecture is designed to support quantum-enhanced sampling for continuous probability distributions used in advanced statistical analysis of clinical trial and biomedical datasets. SciSparc said the latest milestone shows the platform can handle complex, high-dimensional biomedical data while using quantum-inspired and quantum-enabled methods to identify non-obvious patterns and remain aligned with downstream scientific interpretation. The platform is being advanced through CliniQuantum Ltd., a quantum-focused technology initiative in which NeuroThera holds 54.01%. SciSparc said next steps include expanding the scale of supported datasets, optimizing quantum algorithms and running performance studies to assess the potential role of quantum computing in clinical research, clinical trial analytics and precision medicine applications.